Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies

Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History

Chronic Obstructive Pulmonary Disease-I: Introduction

Chronic Obstructive Pulmonary Disease-I: Introduction

Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.

Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations

Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations

Chronic Obstructive Pulmonary Disease, or COPD, is a long-term condition marked by persistent and only partially reversible airflow limitation. It involves two overlapping conditions—chronic bronchitis and emphysema—which often co-appear but differ in dominant symptoms and underlying mechanisms.Chronic Bronchitis FeaturesChronic bronchitis presents with a persistent productive cough and thick, sometimes purulent mucus due to airway inflammation, enlarged mucus glands, and goblet cell...

COPD: Pathogenesis and Clinical Features

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...

Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Safety and efficacy of astegolimab for COPD with frequent exacerbations regardless of baseline blood eosinophil counts (ALIENTO and ARNASA): randomised, double-blind, placebo-controlled, phase 2b and 3 trials.

Lancet (London, England)·2026

Same author

BMN 349, a small molecule inhibitor of Z alpha-1 antitrypsin polymerization, increases secretion and reduces intrahepatic inclusions in a mouse model of disease.

Hepatology (Baltimore, Md.)·2026

Same author

Z variant heterozygosity in alpha-1 antitrypsin deficiency: disease risk and treatment implications.

Orphanet journal of rare diseases·2026

Same author

New approaches to uncover COPD pathobiology and develop therapies.

JCI insight·2026

Same author

Invertebrate Automated Phenotyping Platform (INVAPP): An Automated High-Throughput System with Applications in Understanding and Combating Human Diseases.

Methods in molecular biology (Clifton, N.J.)·2026

Same author

Corrigendum to "Disease burden and health-related outcomes of patients discharged from hospital following a COPD exacerbation in the United States" [Respir. Med. 248 (2025) 108337].

Respiratory medicine·2025

Search research articles

Related Experiment Video

Updated: May 11, 2026

Machine Learning-Based Cough Tone Classification: Diagnostic Exploration of Chronic Obstructive Pulmonary Disease and Respiratory Tract Infections

Machine Learning-Based Cough Tone Classification: Diagnostic Exploration of Chronic Obstructive Pulmonary Disease and Respiratory Tract Infections

Published on: September 19, 2025

The COPD Biomarker Qualification Consortium (CBQC).

Richard Casaburi¹, Bartolome Celli, James Crapo

¹Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Los Angeles, California, USA.

|May 30, 2013

Summary

This summary is machine-generated.

Despite advances in understanding chronic obstructive pulmonary disease (COPD), new treatments are lacking. A collaborative effort, the COPD Biomarkers Qualification Consortium, aims to develop new drug development tools for COPD assessment.

Related Experiment Videos

Last Updated: May 11, 2026

Machine Learning-Based Cough Tone Classification: Diagnostic Exploration of Chronic Obstructive Pulmonary Disease and Respiratory Tract Infections

Machine Learning-Based Cough Tone Classification: Diagnostic Exploration of Chronic Obstructive Pulmonary Disease and Respiratory Tract Infections

Published on: September 19, 2025

Area of Science:

Pulmonary Medicine
Pharmacology
Biomarker Discovery

Background:

Chronic obstructive pulmonary disease (COPD) knowledge has grown significantly, yet therapeutic advancements remain limited.
The development pipeline for new COPD treatments has slowed, with few new medication classes introduced.
Existing tools for assessing new COPD treatments have not evolved with the disease's complex understanding.

Purpose of the Study:

To address the stagnation in novel COPD treatment development.
To facilitate the creation of new tools for evaluating COPD therapies.
To overcome regulatory hurdles in developing and validating drug development tools.

Main Methods:

A workshop convened by the Food and Drug Administration (FDA) with key stakeholders.
Collaboration included the COPD Foundation, National Heart Lung and Blood Institute, pharmaceutical industry, and academia.
Initiation of the COPD Biomarkers Qualification Consortium to integrate existing data.

Main Results:

The workshop identified available information crucial for new tool development.
The COPD Biomarkers Qualification Consortium was established as a collaborative project.
The Consortium is actively preparing integrated datasets to support COPD drug development tools.

Conclusions:

There is a critical need for novel assessment tools to accelerate COPD drug development.
Collaborative initiatives are essential to overcome challenges in biomarker qualification.
The COPD Biomarkers Qualification Consortium represents a significant step towards advancing COPD therapeutic innovation.